Grouped bar charts show total number of funding rounds from three of the most prolific biopharma venture capital firms, RA Capital, OrbiMed and Arch Venture Partners, for each year going from 2022 to 2026. For RA, the totals are 19, 22, 28, 17 and 30 across the five years. For OrbiMed they are 18, 21, 21, 21 and 15. And for Arch they are 21, 17, 23, 15 and 7.